The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis
Kanbay M, Copur S, Siriopol D, Yildiz A, Berkkan M, Popa R, Hasbal N, Ortiz A, Perazella M. The association between acute kidney injury and outcomes in cancer patients receiving immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Clinical Kidney Journal 2022, 16: 817-826. PMID: 37151409, PMCID: PMC10157786, DOI: 10.1093/ckj/sfac194.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsEffect of AKICheckpoint inhibitorsCancer patientsKidney injuryDevelopment of AKISystematic reviewImmune checkpoint inhibitor therapySevere acute kidney injuryPersistent kidney dysfunctionSevere AKI patientsCheckpoint inhibitor therapyRisk of deathNon-randomized studiesCochrane Library databasesRisk of mortalityNovel therapeutic approachesWeb of ScienceAKI patientsICPI treatmentCause mortalityInhibitor therapyKidney dysfunctionMortality outcomesImproving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney International Reports 2022, 7: 1939-1950. PMID: 36090489, PMCID: PMC9458993, DOI: 10.1016/j.ekir.2022.06.005.Peer-Reviewed Original ResearchChronic kidney diseaseEnd-stage kidney diseaseSevere kidney dysfunctionKidney diseaseKidney dysfunctionAdvanced kidney diseaseOptimal clinical careCancer drug trialsNumber of patientsNarrow therapeutic indexInitial clinical studiesKidney replacement treatmentPreregistration studiesKidney functionCancer careReplacement treatmentCancer trialsClinical trialsEffective dosingClinical studiesTreatment decisionsDrug trialsBeneficial drugsClinical carePatients